多发性硬化
医学
大麻
不利影响
大麻素
神经保护
疾病
重症监护医学
药理学
免疫学
精神科
内科学
受体
作者
Roua A. Nouh,Ahmed Kamal,Oluwaseyi Oyewole,Walaa A. Abbas,Bishoy Abib,Abdelrouf Omar,Somaia T. Mansour,Anwar Abdelnaser
出处
期刊:Pharmaceutics
[Multidisciplinary Digital Publishing Institute]
日期:2024-02-07
卷期号:16 (2): 241-241
被引量:12
标识
DOI:10.3390/pharmaceutics16020241
摘要
Multiple sclerosis is the predominant autoimmune disorder affecting the central nervous system in adolescents and adults. Specific treatments are categorized as disease-modifying, whereas others are symptomatic treatments to alleviate painful symptoms. Currently, no singular conventional therapy is universally effective for all patients across all stages of the illness. Nevertheless, cannabinoids exhibit significant promise in their capacity for neuroprotection, anti-inflammation, and immunosuppression. This review will examine the traditional treatment for multiple sclerosis, the increasing interest in using cannabis as a treatment method, its role in protecting the nervous system and regulating the immune system, commercially available therapeutic cannabinoids, and the emerging use of cannabis in nanomedicine. In conclusion, cannabinoids exhibit potential as a disease-modifying treatment rather than merely symptomatic relief. However, further research is necessary to unveil their role and establish the safety and advancements in nano-cannabinoid medicine, offering the potential for reduced toxicity and fewer adverse effects, thereby maximizing the benefits of cannabinoids.
科研通智能强力驱动
Strongly Powered by AbleSci AI